Re-engineered Gleevec eliminates a side effect

Scientists have re-engineered the blockbuster oncology drug Gleevec to eliminate a serious cardiovascular risk, taking a new approach that could offer a significant improvement for "hundreds" of other drugs as well. Gleevec works by targeting the tyrosine kinases involved in cell reproduction, interfering with a key step in the development of cancer. But the drug also interferes with tyrosine kinases in the ABL family, triggering heart problems in some patients. By adding a methyl group to the drug's structure, it will now only affect cell reproduction. Novartis' drug earned $2.6 billion last year.

The scientist Thomas Force told Chemistry World: "The biggest message of this paper is that a cardiotoxic cause can be identified and steered away from. There are hundreds of agents in development that could benefit from this research."

- see the release on Gleevec
- check out the article from Chemistry World

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.